// App-Quantinova.ai

5064 : P53 status in primary tumor predicts efficacy of first-line abiraterone and enzalutamide in castration-resistant prostate cancer patients.

Researchers

Presenter

  • Benjamin Louis Maughan

Principal Investigators

  • Liana Guedes

  • Kenneth M. Boucher

  • Gaurav Rajoria

  • Zach Liu

  • Szczepan Klimek

  • Roberto Zoino

  • Emmanuel S. Antonarakis

  • Tamara L. Lotan

Medical Centers

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Johns Hopkins, Baltimore, MD

  • Pathline Emerge Pathology Services, Ramsey, NJ

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • p53

  • Phosphatase and tensin homolog

  • Tumor protein p53

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved